View Press Releases
-
Integrated DNA Technologies and Molecular Health Ink Commercial Partnership
IDT and Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their NGS capabilities.
May 14, 2024
-
Inceptua Group Expands Early Access Program to Latin America
Inceptua Group announces an expansion of an Early Access Program for cefiderocol for eligible patients in Argentina, Chile, Colombia, Guatemala, Mexico, and Panama.
May 14, 2024
-
Vector Laboratories Merges With Absolute Biotech, Significantly Expanding Capabilities as a Critical Component Manufacturer for Life Science Customers
Vector Laboratories joins forces with Absolute Biotech, bolstering its role as a key manufacturer for life science customers, enriching its antibody reagents portfolio, and expanding its commercial presence into the UK and EU.
May 14, 2024
-
PrecisionLife and Metrodora Institute Launch Clinical Trials to Accelerate the Diagnosis and Treatment of ME/CFS and Long Covid Patients
Metrodora Institute and PrecisionLife announce the start of recruitment on a cohort of up to 1,000 patients into clinical trials to evaluate new diagnosis and treatment options for ME/CFS, Long Covid, and related disorders.
May 13, 2024
-
Indica Labs Receives First FDA Clearance for HALO AP Dx Digital Pathology Platform
Indica Labs announced today that it received FDA clearance for HALO AP Dx, an enterprise digital pathology platform, for primary diagnosis.
May 13, 2024
-
Elegen Raises $35 Million in Series B to Accelerate Expansion into Clinical Manufacturing
Elegen is leveraging their next-generation DNA synthesis and production technology to expand into clinical DNA scaleup and manufacturing, a move supported by this Series B round with new investors Trianomic Capital, GSK, and Aldevron co-founder John Ballantyne as well as existing investors. This expansion into clinical applications comes just a little over a year after launching their first product, ENFINIA DNA. To date the company has rapidly enhanced its platform to speed the upstream discovery phase of genetic medicine development, and in January announced a collaboration and licensing agreement with GSK. Investors are confident that Elegen's cell-free, turnkey synthetic DNA platform will transform the speed and reliability of clinical GMP DNA manufacturing.
May 13, 2024
-
ZeOmega Supports Health Plan Alliance with Payvider Solutions
-
Kalderos Names Healthcare Industry Veteran Daryl Todd as Chief Strategy Officer
Kalderos Names Healthcare Industry Veteran Daryl Todd as Chief Strategy Officer
May 13, 2024
-
InsightRX Continues Momentum in Precision Dosing with Client Growth, New Scientific Breakthroughs
InsightRX Continues Momentum in Precision Dosing with Client Growth, New Scientific Breakthroughs
May 13, 2024
-
Cotiviti Client Conference Brings Together Health Plan Leaders to Strengthen Healthcare Ecosystem through Technology and Expertise
-
PathAI Announces PLUTO: a State-of-the-Art Foundation Model to Enhance AI-powered Pathology Tools
PLUTO’s embeddings will enable prediction of underlying molecular alterations driving cancer and disease phenotypes–including those previously hidden to AI–as well as the discovery of new biomarkers and therapeutic targets.
May 13, 2024
-
Optibrium Partners with FMC Corporation to Transform Agrochemical Discovery
Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline
May 13, 2024
-
FDB Expands its Medication Instructions to Include Translations of Hindi & Punjabi, 2 of the Fastest-Growing Languages in the US
https://www.prnewswire.com/news-releases/fdb-expands-its-medication-instructions-to-include-translations-of-hindi--punjabi-2-of-the-fastest-growing-languages-in-the-us-302141989.html?tc=eml_cleartime
May 12, 2024
-
Switchboard Health Announces $6.5M Series Seed Funding to Support New Partnerships with Health Plans and Value-Based Care Providers
Switchboard Health, creator of a high-value specialty care network and software platform, has secured $6.5 million in series seed funding.
May 12, 2024
-
Torbay Pharma strengthens leadership team to support North American growth strategy
-
Baylor Genetics Launches RNASeq Test for Whole Genome and Whole Exome Sequencing, Reduces Turnaround Times, Introduces Four New Genetic Analysis Panels
Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced the availability of a new RNA sequencing test, RNAseq, for Whole Exome and Whole Genome Sequencing (WES/WGS). The company also reduced its standard turnaround time on WES and WGS to three weeks and continues to provide rapid testing with written reports in as few as five days.
May 12, 2024
-
Watson-Marlow introduces DriveSure® OEM pump solution at ACHEMA 2024
Watson-Marlow Fluid Technology Solutions (WMFTS) will showcase its recently launched DriveSure® panel mount pumps along with other products for life sciences companies at ACHEMA 2024 in Germany (June 10-14).
May 13, 2024
-
Cresset® appoints new Chairman
-
Guy’s and St Thomas’ NHS Foundation Trust Harnesses PhenoTips’ Genomic Health Record to Finalise 5 Year Strategy: Together We Care
Built on the strong visions and values of the Trust, Guy’s and St Thomas’ “Together We Care” strategy centers on three primary priorities, Patients, People, and Partnerships, aiming to bolster patient autonomy, invest in staff, and harness technologies in collaboration with commercial partners. Guy’s and St Thomas’ implementation of PhenoTips’ Genomic Health Record on the final year of their 2018-2023 strategy completes the ambitious 5-year plan by empowering patients to take an active role in the collection of their data, streamlining staff and provider workflows, and establishing a framework for deep integration between the partner technologies supporting the Trust.
May 12, 2024
-
Scientists have discovered a method to treat neurological diseases without heart-related side effects
The biotech startup Lactocore Group has reported unusual properties of a proprietary peptide, LCGA-17m16, aimed at treating neurological disorders without harming the heart that signal a potential paradigm shift in treating neurological disorders.
May 12, 2024